YES Securities' research report on SBI Life Insurance
VNB margin has inched lower on YoY basis for the quarter on account of SBIL choosing not to remain margin neutral during re-pricing: The calculated VNB margin in 4QFY22 is 26.9%, which is 77 bps lower than the calculated VNB margin in 4QFY21. The VNB margin has been flattish to lower on YoY basis despite an apparent improvement in product mix. This is because when SBI Life re-priced products in August, the re-pricing was not fully margin neutral, especially for the non-par savings product basket. Management averred that VNB margin should expand going forward due to rising share of Non-Par Guaranteed business, Deferred Annuities and Protection. The sequential de-growth in APE was mainly on account of the third wave of Covid19, from which SBIL has already bounced back: Total APE was down 10% QoQ to Rs 41.2bn in 4QFY22. This was primarily due to the third wave of Covid-19 impacting sales in January and February. We think the third wave might have impacted SBIL more than peers since a greater proportion its, generally mass market, customers would be dependent on human mobility. Growth has recovered in March and trends are encouraging.
We maintain ‘BUY’ rating on SBIL with a revised price target of Rs 1580: We value SBIL at 3.4x FY23 P/EV for an FY23E/24E RoEV profile of 19.8/20.1%